|
 |
| home > epc > summer 2002 > drug delivery technologies: innovations and market challenges - a report in the biotechnology reports series |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The drug delivery industry has been something of a Cinderella until recently. It is clearly appropriate that as the biotechnology industry becomes more prominent as a source of medicines - albeit typically macromolecules rather than the smaller, organic molecules of the traditional, mainstream pharmaceutical industry - this report should issue in the Biotechnology Reports series. Nevertheless, this report does pay major attention to smaller sized pharmaceutical molecules. The information contained within it is not of a highly technical nature. However, there are already many publications meeting the needs of the pharmaceutical scientist active in the area. This report addresses the non-technical needs of this and other audiences.
An introductory chapter makes the case for the importance of drug delivery in the development of both novel compounds and established products. The various advantages of drug delivery technologies are delineated, as are the various barriers which drug delivery technologies seek to address. A useful discussion of how pharmaceutical and biotechnological industry dynamics are underpinning a growth rate of 15 to 20 per cent per year in the drug delivery industry, is enhanced by useful examples such as patent extension strategies for Eli Lilly with Prozac and AstraZeneca with Losec.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
A review by Dr Roy Drucker, General Manager of Technomark Consulting Services Limited
Roy Drucker joined the European R&D arm of Sterling Drug Inc as a Medical Advisor. He was promoted to being responsible for clinical pharmacology, drug metabolism and bioanalysis in Europe. In 1986 he moved to the Upjohn Company, subsequently Pharmacia & Upjohn, Inc., where he held a range of international responsibilities. His positions there included Director of Marketing with responsibility for worldwide marketing of cardiovascular products; Executive Director, European Community Affairs and Business Systems; and Vice-President, Drug Development, with global responsibility in multiple therapeutic areas for clinical drug development and medical support for marketed products.
A graduate of the Harvard Business School Advanced Management Program, a member of the Securities Institute and an FSA registered Approved Person, Roy has been based in Belgium, the UK, and the US. He has been General Manager of Technomark since September 1996.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
